Lepidic growth component as a favorable prognostic factor in non-small cell lung cancer

Lepidic growth component as a favorable prognostic factor in non-small cell lung cancer - Lepidic growth component is prognostic factor

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047614

Enrollment

975

Registered

2022-04-30

Start date

2021-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criterion was complete resected NSCLC.

Exclusion criteria

Exclusion criteria: The exclusion criteria were as follows: a) diagnosis of small cell lung cancer of any size, adenocarcinoma in situ, or synchronous lung cancer; b) previous preoperative chemotherapy or radiotherapy; c) stage IV disease; and d) insufficient data lacking clinical, pathological, or prognostic information.

Design outcomes

Primary

Measure	Time frame
We retrospectively reviewed the clinicopathologic features of 379 patients with NSCLC who underwent radical surgical resection between 2004 and 2016 at the University of Yamanashi Hospital. The histologic subtypes were classified into the LGC group (NSCLC with an LGC) and the non-LGC group (NSCLC without an LGC). We evaluated the effect of an LGC on the clinicopathologic features and 5-year overall survival of patients with NSCLC using a Cox proportional hazards model and a log-rank test by matching with the pathologic invasive size.	—

Measure

Time frame

We retrospectively reviewed the clinicopathologic features of 379 patients with NSCLC who underwent radical surgical resection between 2004 and 2016 at the University of Yamanashi Hospital. The histologic subtypes were classified into the LGC group (NSCLC with an LGC) and the non-LGC group (NSCLC without an LGC). We evaluated the effect of an LGC on the clinicopathologic features and 5-year overall survival of patients with NSCLC using a Cox proportional hazards model and a log-rank test by matching with the pathologic invasive size.

—

Countries

Japan

Contacts

Public ContactDaisuke Sato

University of Yamanashi Department of Thoracic Surgery

satoh.dsuke@gmail.com055-273-1111

Outcome results